Description: Immunic, Inc. (Nasdaq:IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORĪ³t; and IMU-856 targets the restoration of the intestinal barrier function. Immunic's lead development program, IMU-838, is in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional phase 2 trial in Crohn's disease planned for 2019. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is planned to start at the Mayo Clinic.
Home Page: www.immunic-therapeutics.com
IMUX Technical Analysis
1200 Avenue of the Americas
New York,
NY
10036
United States
Phone:
332 255 9818
Officers
| Name | Title |
|---|---|
| Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A | Exec. Chairman |
| Dr. Daniel Vitt | CEO, Pres & Director |
| Mr. Glenn Whaley CPA | Chief Financial Officer |
| Dr. Andreas Muehler M.D., Ph.D. | Chief Medical Officer |
| Dr. Hella Kohlhof | Chief Scientific Officer |
| Jessica Breu | Head of Investor Relations & Communications |
| Mr. Inderpal Singh | Gen. Counsel |
| Mr. Patrick Walsh | Chief Bus. Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4258 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2014-04-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 65 |